Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Ludwig-Maximilians-Universität München · BC Cancer Agency · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
611
total citations
- FWCI
- 34.96
- Percentile
- 100%
- References
- 39
Citations per year
Authors
35- APAlessandro Pastore
Ludwig-Maximilians-Universität München
- VJVindi Jurinović
Ludwig-Maximilians-Universität München
- RKRobert Kridel
BC Cancer Agency
- EHEva Hoster
Ludwig-Maximilians-Universität München
- AMAnnette M. Staiger
Robert Bosch Hospital, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, University of Tübingen
Topics & keywords
Topics
Keywords
- Medicine
- Rituximab
- Follicular lymphoma
- Internal medicine
- Oncology
- Population
- Vincristine
- Prednisone
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- CCelgene
- GCGenome Canada
- MSMichael Smith Health Research BC
- GBGenome British Columbia
- TFTerry Fox Research Institute
- UOUniversity of British Columbia
- DKDeutsche KrebshilfeAward: 110659
- DMDr. Mildred Scheel Stiftung für Krebsforschung
- ABAlfred Benzon Foundation
- HLH. Lundbeck A/S
- CICanadian Institutes of Health Research
- BCBC Cancer Agency